Contact your clinical team promptly if you experience: Persistent vomiting that prevents you from keeping food or fluids down for more than 24 hours Signs of dehydration including dark urine, dizziness, dry mouth, or significantly reduced urine output Unexplained or severe abdominal pain, which may rarely indicate pancreatitis a serious but recognised risk with GLP-1based therapies [21] [22] Persistent pain in the upper right side of your abdomen, particularly if accompanied by fever, jaundice (yellowing of the skin or whites of the eyes), pale stools, or dark urine these may be signs of gallbladder disease, which can occur with rapid weight loss and with GLP-1based medicines, and requires prompt assessment [20] Unintentional weight loss that feels excessive or rapid beyond what has been discussed as a treatment goal Symptoms suggestive of nutritional deficiency, such as persistent fatigue, hair thinning, muscle weakness, or low mood It is also advisable to seek a dietitian referral early in treatment, ideally before starting retatrutide or during the initial dose escalation phase

Nerve and tissue repair: Research shows GHK-Cu promotes neurite outgrowth and supports repair of nerve tissue, making it a candidate peptide for post-surgical or neuropathy-adjacent protocols
And standard testing often misses the bigger picture
Additionally, the grey market for GLP1 drugs can create a significant public health concern